168
Participants
Start Date
May 19, 2020
Primary Completion Date
June 24, 2021
Study Completion Date
June 24, 2021
Androderm®
Androderm® transdermal dose.
Manhattan Medical Research Practice, PLLC, New York
AccuMed Research Associates, Garden City
MidLantic Urology, Bala-Cynwyd
Virginia Urology, Richmond
Urology of Virginia, Virginia Beach
Associated Urologist of North Carolina, Raleigh
Physicians Research Associates, LLC, Lawrenceville
Endocrine Consultants Newnan, Newnan
Atlanta Diabetes Associates, Atlanta
Columbus Regional Research Institute, Columbus
Ovieo Medical Research, LLC, Oviedo
South Florida Medical Research, Aventura
Precision Clinical Research, LLC, Sunrise
Metabolic Research Institute, Inc., West Palm Beach
Florida Urology Partners, Tampa
Meridien Research, St. Petersburg
Renstar Medical Research, Ocala
Central Research Associates, Inc., Birmingham
Coastal Clinical Research, LLC, An AMR Co., Mobile
The Iowa Clinic, West Des Moines
DelRicht Research, LLC, New Orleans
Regional Urology, LLC, Shreveport
AIM Trials, LLC, Plano
SMS Clinical Research, LLC2, Mesquite
Diabetes & Glandular Disease Clinic, P.A., San Antonio
Texas Diabetes & Endocrinology, Round Rock
Texas Diabetes & Endocrinology, Austin
Texas Diabetes & Endocrinology, P.A., Austin
Academy of Diabetes Thyroid and Endocrine, El Paso
Creekside Endocrine Associates, PC, Denver
Idoho Urologic Institute, Meridian
Urological Associates of South Arizona, PC, Tucson
WR - Clinical Research Center of Nevada, LLC, Las Vegas
Hope Clinical Research, Canoga Park
Care Access Research, Santa Clarita
San Diego Clinical Trials, La Mesa
Wr-McCr, Llc, San Diego
Marvel Clinical Research, Huntington Beach
Rainier Clinical Research Center, Inc, Renton
Bay State Clinical Trials, Inc, Watertown
Premier Urology Group, Edison
Lead Sponsor
Allergan
INDUSTRY